Alkermes (ALKS) EPS (Diluted) Growth (3y) (2013 - 2026)
Alkermes (ALKS) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -87.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.25% |
| Mar 31, 2026 | -21.85% |
| Dec 31, 2025 | -18.28% |
| Dec 31, 2024 | -79.60% |
| Sep 30, 2024 | 74.78% |
| Jun 30, 2024 | -53.08% |
| Mar 31, 2024 | 53.12% |
| Dec 31, 2023 | 3.58% |
| Sep 30, 2023 | -578.82% |
| Jun 30, 2023 | -9.81% |
| Mar 31, 2023 | 5.13% |
| Dec 31, 2022 | 61.95% |
| Sep 30, 2022 | -3.19% |
| Jun 30, 2022 | 13.22% |
| Mar 31, 2022 | 30.07% |
| Dec 31, 2021 | 84.55% |
| Sep 30, 2021 | 8.04% |
| Jun 30, 2021 | 27.36% |
| Mar 31, 2021 | 30.41% |
| Dec 31, 2020 | -59.96% |